Quotas - 2020
[Federal Register Volume 85, Number 170 (Tuesday, September 1, 2020)]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-19308]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-508A2]
Proposed Adjustments to the Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2020
AGENCY: Drug Enforcement Administration, Department of Justice.
ACTION: Notice with request for comments.
SUMMARY: The Drug Enforcement Administration proposes to adjust the 2020 aggregate production quotas for several controlled substances in schedules I and II of the Controlled Substances Act and assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.
DATES: Interested persons may file written comments on this notice in accordance with 21 CFR 1303.13(c) and 1315.13(d). Electronic comments must be submitted, and written comments must be postmarked, on or before October 1, 2020. Commenters should be aware that the electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period.
Based on comments received in response to this notice, the Administrator may hold a public hearing on one or more issues raised. In the event the Administrator decides in his sole discretion to hold such a hearing, the Administrator will publish a notice of any such hearing in the Federal Register. After consideration of any comments or objections, or after a hearing, if one is held, the Administrator will publish in the Federal Register a final order establishing the 2020 adjusted aggregate production quotas for schedule I and II controlled substances, and an adjusted assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.
ADDRESSES: To ensure proper handling of comments, please reference "Docket No. DEA-508A2" on all correspondence, including any attachments. DEA encourages that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or to attach a file for lengthier comments. Please go to http://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon completion of your submission, you will receive a Comment Tracking Number for your comment. Please be aware that submitted comments are not instantaneously available for public view on Regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. Paper comments that duplicate electronic submissions are not necessary and are discouraged. Should you wish to mail a paper comment in lieu of an electronic comment, it should be sent via regular or express mail to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152.
FOR FURTHER INFORMATION CONTACT: Scott A. Brinks, Regulatory Drafting and Policy Support Section, Diversion Control Division, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, Virginia 22152, Telephone: (571) 362-3261.
Posting of Public Comments
Please note that all comments received in response to this docket are considered part of the public record. They will, unless reasonable cause is given, be made available by the Drug Enforcement Administration (DEA) for public inspection online at http://www.regulations.gov. Such information includes personal identifying information (such as your name, address, etc.) voluntarily submitted by the commenter.
The Freedom of Information Act applies to all comments received. If you want to submit personal identifying information (such as your name, address, etc.) as part of your comment, but do not want it to be made publicly available, you must include the phrase "PERSONAL IDENTIFYING INFORMATION" in the first paragraph of your comment. You must also place all the personal identifying information you do not want made publicly available in the first paragraph of your
comment and identify what information you want redacted.
If you want to submit confidential business information as part of your comment, but do not want it to be made publicly available, you must include the phrase "CONFIDENTIAL BUSINESS INFORMATION" in the first paragraph of your comment. You must also prominently identify confidential business information to be redacted within the comment.
Comments containing personal identifying information or confidential business information identified and located as directed above will generally be made available in redacted form. If a comment contains so much confidential business information or personal identifying information that it cannot be effectively redacted, all or part of that comment may not be made publicly available. Comments posted to http://www.regulations.gov may include any personal identifying information (such as name, address, and phone number) included in the text of your electronic submission that is not identified as directed above as confidential.
An electronic copy of this document is available at http://www.regulations.gov for easy reference.
Legal Authority and Background
Section 306 of the Controlled Substances Act (CSA) (21 U.S.C. 826) requires the Attorney General to establish aggregate production quotas for each basic class of controlled substances listed in schedules I and II and for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. The Attorney General has delegated this function to the Administrator of the DEA pursuant to 28 CFR 0.100.
DEA established the 2020 aggregate production quotas for substances in schedules I and II and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine on December 2, 2019 (84 FR 66014). That order stipulated that, in accordance with 21 CFR 1303.13 and 1315.13, all aggregate production quotas and assessments of annual need are subject to adjustment. DEA issued a notice and final order on April 10, 2020, to adjust the 2020 aggregate production quota for certain schedule II controlled substances and the assessment of annual needs for ephedrine and pseudoephedrine (85 FR 20302) in response to the coronavirus disease 2019 public health emergency.
Analysis for Proposed Adjusted 2020 Aggregate Production Quotas and Assessment of Annual Needs
DEA proposes to adjust the established 2020 aggregate production quotas and assessment of annual needs for certain schedule I and II controlled substances, and the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, to be manufactured in the United States in 2020 to provide for the estimated medical, scientific, research, and industrial needs of the United States, for lawful export requirements, and for the establishment and maintenance of reserve stocks. These quotas do not include imports of controlled substances for use in industrial processes.
Factors for Determining the Proposed Adjustments
In determining the proposed adjustment, the Acting Administrator has taken into account the criteria in accordance with 21 CFR 1303.13 (adjustment of aggregate production quotas for controlled substances) and 21 CFR 1315.13 (adjustment of the assessment of annual needs for ephedrine, pseudoephedrine, and phenylpropanolamine). The Acting Administrator is authorized to increase or reduce the aggregate production quota at any time. 21 CFR 1303.13(a) and 1315.13(a). DEA regulations state that there are five factors that shall be considered in determining to adjust the aggregate production quota and the assessment of annual needs. 21 CFR 1303.13(b) and 1315.13(b).
DEA determined whether to propose an adjustment of the aggregate production quotas and assessment of annual needs for 2020 by considering: (1) Changes in the demand for that class or chemical, changes in the national rate of net disposal of the class or chemical, changes in the national rate of net disposal of the class or chemical by registrants holding individual manufacturing quotas for that class or chemical or import quotas for that chemical, and changes in the extent of any diversion in the class of controlled substance; (2) whether any increased demand for that class or chemical, the national and/or individual rates of net disposal of that class or chemical are temporary, short term, or long term; (3) whether any increased demand for that class or chemical can be met through existing inventories, increased individual manufacturing quotas, or increased importation, without increasing the aggregate production quota or assessment of annual needs, taking into account production delays and the probability that other individual manufacturing quotas may be suspended pursuant to Sections 1303.24(b) and 1315.24(b); (4) whether any decreased demand for that class or chemical will result in excessive inventory accumulation by all persons registered to handle that class or chemical (including manufacturers, distributors, practitioners, importers, and exporters), notwithstanding the possibility that individual manufacturing quotas may be suspended pursuant to Sections 1303.24(b) and 1315.24(b) or abandoned pursuant to Sections 1303.27 and 1315.27; and (5) other factors affecting medical, and reserve stocks, scientific, research, and industrial needs in the United States, lawful export requirements, and other factors affecting importation needs of listed chemicals in the United States as the Acting Administrator finds relevant, including changes in the currently accepted medical use in treatment with the class or chemical or the substances which are manufactured from it, the economic and physical availability of raw materials for use in manufacturing and for inventory purposes, yield and stability problems, potential disruptions to production (including possible labor strikes), and recent unforeseen emergencies such as floods and fires. 21 CFR 1303.13(b) and 1315(b). These quotas do not include imports of controlled substances for use in industrial processes.
DEA considered the change in the extent of diversion of all controlled substances in proposing adjustments to the aggregate production quotas as required by 21 CFR 1303.13(b)(1). Through these considerations, it has been determined that any calculated changes from the previously determined initial calculations are slight and statistically indistinguishable from the quantities originally calculated for the extent of diversion that were applied to the initial aggregate production quota valuations.
DEA also considered updated information obtained from 2019 year-end inventories, 2019 disposition data submitted by quota applicants, estimates of the medical needs of the United States, product development, and other information made available to DEA after the initial aggregate production quotas and assessment of annual needs had been established. Other factors the Acting Administrator considered in calculating the aggregate production quotas, but not the assessment of annual needs, include product development requirements of both bulk and finished dosage form
manufacturers, and other pertinent information. In determining the proposed adjusted 2020 assessment of annual needs, DEA used the calculation methodology previously described in the 2010 and 2011 assessment of annual needs (74 FR 60294, Nov. 20, 2009, and 75 FR 79407, Dec. 20, 2010, respectively).
Considerations Based Upon the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act
Pursuant to 21 U.S.C. 826(a)(1), "production quotas shall be established in terms of quantities of each basic class of controlled substance and not in terms of individual pharmaceutical dosage forms prepared from or containing such a controlled substance." However, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018 (SUPPORT Act), Pub. L. 115-271, provides an exception to that general rule by now giving DEA the authority to establish quotas in terms of pharmaceutical dosage forms if the agency determines that doing so will assist in avoiding the overproduction, shortages, or diversion of a controlled substance.
DEA has stated before that while there is the authority to set aggregate production quotas in terms of pharmaceutical dosage form, DEA will not be using that authority at this time. Furthermore, when DEA does utilize the authority, it will be doing so at the individual dosage-form manufacturing level, as that is where it is most appropriate to do so. As such, there are no adjustments to set any controlled substances in terms of pharmaceutical dosage forms.
Under the SUPPORT Act, when setting the aggregate production quota, DEA must estimate the amount of diversion of any substance that is considered a "covered controlled substance," as defined by the SUPPORT Act. 21 U.S.C. 826(i)(1)(A). The covered controlled substances are fentanyl, oxycodone, hydrocodone, oxymorphone, and hydromorphone. The SUPPORT Act also requires DEA to "make appropriate quota reductions, as determined by the [Administrator],\1\ from the quota the [Administrator] would have otherwise established had such diversion not been considered." 21 U.S.C. 826(i)(1)(C). When estimating diversion, the "[Administrator] (i) shall consider information the [Administrator], in consultation with the Secretary of Health and Human Services, determines reliable on rates of overdose deaths and abuse and overall public health impact related to the covered controlled substance in the United States; and (ii) may take into consideration whatever other sources of information the [Administrator] determines reliable." \2\ Id.
\1\ All functions vested in the Attorney General by the CSA have been delegated to the Administrator of DEA. 28 CFR 0.100(b).
\2\ DEA intends to finalize amendments to the Agency's regulations that will implement the amendments to the CSA made by the SUPPORT Act. Although these amendments to the regulations have not yet been issued, the statutory requirements stated above became effective upon enactment of the SUPPORT Act, and DEA is therefore obligated to adhere to them in issuing these adjusted aggregate production quotas.
DEA consulted with the U.S. Department of Health and Human Services (HHS) and DEA was advised that the Centers for Disease Control and Prevention (CDC) may have data that can provide reliable rates of overdose deaths. CDC provided DEA with data from their National Vital Statistics System-Mortality files. CDC determined that the current available data, calendar year 2016, regarding rates of overdose deaths and public health impact does not reflect each controlled substance individually (i.e., as a basic class and the quantity ingested), but groups them together functionally (opioid or psychostimulant), without regard to illicit or licit manufacturing. Without specificity to basic class and whether the substance was lawfully manufactured, DEA is unable to determine the basic class that led to the overdose from this information. DEA cannot determine from the data if the patient overdosed on an illicit opioid or a U.S. Food and Drug Administration-approved opioid product. Nor can DEA determine if the overdose was a result of accidental or intentional ingestion. As such, the number of overdose deaths resulting from fentanyl, oxycodone, hydrocodone, hydromorphone, and oxymorphone diverted from legitimate sources is unknown. The overdose deaths provided by CDC in its current form cannot be reliably utilized to estimate the amount of diversion for the five covered controlled substances in 2020.
In further consultation with HHS, DEA was advised that the Centers for Medicare and Medicaid Services (CMS) may have reliable rates of overprescribing. DEA was informed by CMS that CMS had reviewed their internal databases and does not have the ability to systematically distinguish between appropriate and inappropriate prescriptions without investigations.
To update the estimates of diversion, DEA used data from the Drug Theft and Loss Report, Statistical Management Analysis & Reporting Tools System, and System to Retrieve Information on Drug Evidence databases to aggregate the active pharmaceutical ingredient (API) of each covered controlled substance by metric weight. From the databases, DEA gathered data involving employee theft, break-ins, armed robberies, and material lost in transit. DEA also used seizure data obtained from submitted reports by law enforcement agencies nationwide. This data was categorized by basic drug class and the amount of API in the dosage form was delineated with an appropriate metric for use in proposing the adjusted aggregate production quota values. Using the data, DEA calculated the estimates for the amount of diversion by multiplying the strength of the API listed for each finished dosage form by the total amount of units reported to estimate the metric weight in kilograms of the controlled substance being diverted. In DEA's previous adjustment for 2020, the diversion estimates were listed for fentanyl, hydromorphone, and oxymorphone, as those were the only covered controlled substances being adjusted. (April 10, 2020, 85 FR 20302.) Below, DEA has updated the chart to include estimations of diversion for each of the other covered controlled substances that will have proposed adjustments from what was established.
|Diversion Estimates for 2019 (kg)|
Proposed Adjustments for the 2020 Aggregate Production Quotas and Assessment of Annual Needs
The Acting Administrator, therefore, proposes to adjust the 2020 aggregate production quotas for certain schedule I and II controlled substances and assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, expressed in grams of anhydrous acid or base, as follows:
|FUB-AMB, MMB-FUBINACA, AMB-FUBINACA||N/A||25|
|1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201)||30||no change|
|1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694)||30||no change|
|2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)||30||no change|
|2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)||30||no change|
|2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N)||30||no change|
|2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P)||30||no change|
|2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)||100||no change|
|2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36)||30||no change|
|2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)||30||no change|
|2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82)||25||no change|
|2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)||30||no change|
|2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5)||30||no change|
|2,5-Dimethoxy-4-ethylamphetamine (DOET)||25||no change|
|2,5-Dimethoxyamphetamine (DMA)||25||no change|
|2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2)||30||no change|
|2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4)||30||no change|
|3,4-Methylenedioxyamphetamine (MDA)||55||no change|
|3,4-Methylenedioxymethamphetamine (MDMA)||50||no change|
|3,4-Methylenedioxy-N-ethylamphetamine (MDEA)||40||no change|
|3,4-Methylenedioxy-N-methylcathinone (methylone)||40||no change|
|3,4-Methylenedioxypyrovalerone (MDPV)||35||no change|
|3-Fluoro-N-methylcathinone (3-FMC)||25||no change|
|4-Bromo-2,5-dimethoxyamphetamine (DOB)||30||no change|
|4-Bromo-2,5-dimethoxyphenethylamine (2-CB)||25||no change|
|4-Chloro-alpha-pyrrolidinovalerophenone (4-chloro-alpha-PVP)||25||no change|
|4CN-Cumyl-Butinaca, 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboximide||25||no change|
|4-Fluoroisobutyryl fentanyl||30||no change|
|4-Fluoro-N-methylcathinone (4-FMC; Flephedrone)||25||no change|
|4-Methyl-N-ethylcathinone (4-MEC)||25||no change|
|4-Methyl-2,5-dimethoxyamphetamine (DOM)||25||no change|
|4-Methyl-N-methylcathinone (mephedrone)||45||no change|
|4-Methyl-alpha-ethylaminopentiophenone (4-MEAP)||25||no change|
|4-Methyl-alpha-pyrrolidinohexiophenone (MPHP)||25||no change|
|4-Methyl-alpha-pyrrolidinopropiophenone (4-MePPP)||25||no change|
|5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog)||40||no change|
|5F-AB-PINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide||25||no change|
|5F-CUMYL-P7AICA; (1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboximide)||25||no change|
|5F-ADB; 5F-MDMB-PINACA (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate)||30||no change|
|5F-AMB (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate)||30||no change|
|5F-APINACA; 5F-AKB48 (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide)||30||no change|
|5-Fluoro-PB-22; 5F-PB-22||20||no change|
|5-Fluoro-UR144, XLR11 ([1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone||25||no change|
|ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide)||30||no change|
|Acetyl Fentanyl||100||no change|
|Acryl Fentanyl||25||no change|
|ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide)||50||no change|
|Alpha-Methyltryptamine (AMT)||25||no change|
|Alpha-Pyrrolidinobutiophenone (α-PBP)||25||no change|
|Alpha-Pyrrolidinoheptaphenone (PV8)||25||no change|
|Alpha-Pyrrolidinohexanophenone (α-PHP)||25||no change|
|Alpha-Pyrrolidinopentiophenone (α-PVP)||25||no change|
|APINACA, AKB48 (N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide)||25||no change|
|Butyryl fentanyl||30||no change|
|Codeine methylbromide||30||no change|
|Cyclopentyl Fentanyl||30||no change|
|Cyclopropyl Fentanyl||20||no change|
|Dioxyaphetyl butyrate||25||no change|
|Fentanyl related substances||40||600|
|Furanyl fentanyl||30||no change|
|Isobutyryl Fentanyl||25||no change|
|JWH-018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole)||35||no change|
|JWH-019 (1-Hexyl-3-(1-naphthoyl)indole)||45||no change|
|JWH-073 (1-Butyl-3-(1-naphthoyl)indole)||45||no change|
|JWH-081 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole)||30||no change|
|JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole)||30||no change|
|JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole)||35||no change|
|JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole)||30||no change|
|JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole)||30||no change|
|JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole)||30||no change|
|Lysergic acid diethylamide (LSD)||40||no change|
|MAB-CHMINACA; ADB-CHMINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide)||30||no change|
|MDMB-CHMICA; MMB-CHMINACA(methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate)||30||no change|
|MDMB-FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate)||30||no change|
|MMB-CHMICA-(AMB-CHMICA); Methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate||25||no change|
|Methyoxyacetyl fentanyl||30||no change|
|Morphine methylbromide||5||no change|
|Morphine methylsulfonate||5||no change|
|NM2201; Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate||25||no change|
|N-Ethyl-3-piperidyl benzilate||10||no change|
|N-Ethylpentylone, ephylone||30||no change|
|N-Methyl-3-Piperidyl Benzilate||30||no change|
|Ortho-fluorofentanyl, 2-fluorofentanyl||30||no change|
|Para-chloroisobutyryl fentanyl||30||no change|
|Para-fluorobutyryl fentanyl||25||no change|
|Para-methoxybutyryl fentanyl||30||no change|
|PB-22; QUPIC||20||no change|
|SR-18 and RCS-8 (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole)||45||no change|
|SR-19 and RCS-4 (1-Pentyl-3-[(4-methoxy)-benzoyl]indole)||30||no change|
|Tetrahydrofuranyl fentanyl||15||no change|
|THJ-2201 ([1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone)||30||no change|
|UR-144 (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone||25||no change|
|Valeryl fentanyl||25||no change|
|4-Anilino-N-phenethyl-4-piperidine (ANPP)||934,956||no change|
|Amphetamine (for conversion)||14,137,578||no change|
|Amphetamine (for sale)||47,000,000||42,400,000|
|Codeine (for conversion)||3,225,000||no change|
|Codeine (for sale)||35,341,292||no change|
|Diphenoxylate (for conversion)||14,100||no change|
|Diphenoxylate (for sale)||770,800||no change|
|Etorphine hydrochloride||32||no change|
|Hydrocodone (for conversion)||1,250||no change|
|Hydrocodone (for sale)||34,836,854||33,997,285|
|Meperidine Intermediate-A||30||no change|
|Meperidine Intermediate-B||30||no change|
|Meperidine Intermediate-C||30||no change|
|Methadone (for sale)||25,619,700||no change|
|Methadone Intermediate||27,673,600||no change|
|[678,878 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 505,231 grams for methamphetamine mostly for conversion to a schedule III product; and 29,494 grams for methamphetamine (for sale)]|
|Morphine (for conversion)||4,089,000||3,376,696|
|Morphine (for sale)||33,756,703||no change|
|Noroxymorphone (for conversion)||22,044,741||no change|
|Noroxymorphone (for sale)||376,000||no change|
|Opium (powder)||250,000||no change|
|Opium (tincture)||530,837||no change|
|Oxycodone (for conversion)||914,010||725,998|
|Oxycodone (for sale)||67,593,983||65,667,554|
|Oxymorphone (for conversion)||28,204,371||no change|
|Oxymorphone (for sale)||829,051||658,515|
|List I Chemicals|
|Ephedrine (for conversion)||25||100|
|Ephedrine (for sale)||4,756,000||no change|
|Phenylpropanolamine (for conversion)||14,100,000||no change|
|Phenylpropanolamine (for sale)||7,990,000||16,590,000|
|Pseudoephedrine (for conversion)||1,000||no change|
|Pseudoephedrine (for sale)||200,382,900||no change|
The Acting Administrator further proposes that aggregate production quotas for all other schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 remain at zero. In accordance with 21 CFR 1303.13 and 21 CFR 1315.13, upon consideration of the relevant factors, the Acting Administrator may adjust the 2020 aggregate production quotas and assessment of annual needs as needed.
After consideration of any comments or objections, or after a hearing, if one is held, the Acting Administrator will issue and publish in the Federal Register a final order establishing any adjustment of 2020 aggregate production quota for each basic class of controlled substances in schedules I and II and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. 21 CFR 1303.13(c) and 1315.13(f).
Timothy J. Shea,
[FR Doc. 2020-19308 Filed 8-31-20; 8:45 am]
BILLING CODE P
NOTICE: This is an unofficial version. An official version of this publication may be obtained directly from the Government Publishing Office (GPO).